Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Inks Non-RNAi Tech-Evaluation Deal with Merck Subsidiary

Premium

Arrowhead Research said this week that it has signed a deal under which an undisclosed Merck subsidiary will evaluate a novel therapeutic monoclonal antibody candidate developed through its human-derived peptide targeting and discovery program.

Merck will be responsible for the costs associated with the arrangement. Additional terms were not disclosed.

Arrowhead picked up the peptide technology through its April acquisition of Alvos Therapeutics (GSN 4/12/2012).

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.